Baidu
map

CID:从1994年到2018年美国带状疱疹和疱疹后神经痛发病率的变化

2021-09-14 从医路漫漫 MedSci原创

近几十年来,带状疱疹(HZ)的发病率呈上升趋势。虽然已经有两种HZ疫苗,但自从HZ和疱疹后神经痛(PHN)发生以来,很少有关于发病率的研究。

目的:近几十年来,带状疱疹(HZ)的发病率呈上升趋势。虽然已经有两种HZ疫苗,但自从HZ和疱疹后神经痛(PHN)发生以来,很少有关于发病率的研究。这项研究调查了美国1994-2018年赫兹和PHN的发病率,以确定自引入带状疱疹疫苗以来,它们是否继续增加。

方法:使用OptumLabs®数据仓库的非识别纵向行政索赔数据库,评估连续登记在数据库中≥365天且无HZ或PHN既往史的个人的发病率。非标准化和标准化发病率按年份、10岁年龄组、性别和种族/民族进行计算。

结果:61066例HZ患者(中位年龄,56.3岁[IQR: 43.0, 68.7]岁;59.8%的女性;白人占70.6%)。1994-2018年,HZ发病率从每10万人年286.0例(95% CI: 259.1, 312.8)上升至579.6例(95% CI: 554.2, 605.0),年增长率3.1% (95% CI: 2.5, 3.6)。自2007年以来,≤20岁和≥60岁人群的年HZ发病率有所下降。PHN的总发病率为每10万人年57.5例(95% CI: 56.0, 59.0)。2007 - 2018年HZ患者发生PHN的比例高于1994 - 2006年。

图1 1994 - 2018年按年龄分列的带状疱疹发病率

图2 1994年至2006年按性别分列的带状疱疹发病率的年变化与2007年至2018年的年变化

图3 1994年至2006年各种族带状疱疹发病率的年变化与2007年至2018年

图4 1994至2006年按年龄划分的带状疱疹患者疱疹后神经痛的比例与2007至2018年的比例

结论:在目前不推荐注射HZ疫苗的年龄组中,带状疱疹发病率持续上升,有必要对目前的疫苗推荐进行重新审查。

原文出处

Thompson RR,  Kong CL,  Porco TC,et al,Herpes Zoster and Post-Herpetic Neuralgia: Changing Incidence Rates from 1994 to 2018 in the United States.Clin Infect Dis 2020 Aug 23

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1823749, encodeId=06451823e49ce, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Thu Jul 14 01:55:59 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991632, encodeId=00071991632d3, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Apr 28 07:55:59 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210068, encodeId=74fb121006863, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c995401287, createdName=ms4000000579625590, createdTime=Sun Apr 10 17:04:15 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540841, encodeId=f9ad154084155, content=<a href='/topic/show?id=ac8de440615' target=_blank style='color:#2F92EE;'>#神经痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74406, encryptionId=ac8de440615, topicName=神经痛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d8213287489, createdName=贵阳, createdTime=Thu Sep 16 01:55:59 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580470, encodeId=3f9c15804e0db, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Thu Sep 16 01:55:59 CST 2021, time=2021-09-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1823749, encodeId=06451823e49ce, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Thu Jul 14 01:55:59 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991632, encodeId=00071991632d3, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Apr 28 07:55:59 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210068, encodeId=74fb121006863, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c995401287, createdName=ms4000000579625590, createdTime=Sun Apr 10 17:04:15 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540841, encodeId=f9ad154084155, content=<a href='/topic/show?id=ac8de440615' target=_blank style='color:#2F92EE;'>#神经痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74406, encryptionId=ac8de440615, topicName=神经痛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d8213287489, createdName=贵阳, createdTime=Thu Sep 16 01:55:59 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580470, encodeId=3f9c15804e0db, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Thu Sep 16 01:55:59 CST 2021, time=2021-09-16, status=1, ipAttribution=)]
    2022-04-28 xlxchina
  3. [GetPortalCommentsPageByObjectIdResponse(id=1823749, encodeId=06451823e49ce, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Thu Jul 14 01:55:59 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991632, encodeId=00071991632d3, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Apr 28 07:55:59 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210068, encodeId=74fb121006863, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c995401287, createdName=ms4000000579625590, createdTime=Sun Apr 10 17:04:15 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540841, encodeId=f9ad154084155, content=<a href='/topic/show?id=ac8de440615' target=_blank style='color:#2F92EE;'>#神经痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74406, encryptionId=ac8de440615, topicName=神经痛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d8213287489, createdName=贵阳, createdTime=Thu Sep 16 01:55:59 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580470, encodeId=3f9c15804e0db, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Thu Sep 16 01:55:59 CST 2021, time=2021-09-16, status=1, ipAttribution=)]
    2022-04-10 ms4000000579625590

    学习一下

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1823749, encodeId=06451823e49ce, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Thu Jul 14 01:55:59 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991632, encodeId=00071991632d3, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Apr 28 07:55:59 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210068, encodeId=74fb121006863, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c995401287, createdName=ms4000000579625590, createdTime=Sun Apr 10 17:04:15 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540841, encodeId=f9ad154084155, content=<a href='/topic/show?id=ac8de440615' target=_blank style='color:#2F92EE;'>#神经痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74406, encryptionId=ac8de440615, topicName=神经痛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d8213287489, createdName=贵阳, createdTime=Thu Sep 16 01:55:59 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580470, encodeId=3f9c15804e0db, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Thu Sep 16 01:55:59 CST 2021, time=2021-09-16, status=1, ipAttribution=)]
    2021-09-16 贵阳
  5. [GetPortalCommentsPageByObjectIdResponse(id=1823749, encodeId=06451823e49ce, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Thu Jul 14 01:55:59 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991632, encodeId=00071991632d3, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Thu Apr 28 07:55:59 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210068, encodeId=74fb121006863, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c995401287, createdName=ms4000000579625590, createdTime=Sun Apr 10 17:04:15 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540841, encodeId=f9ad154084155, content=<a href='/topic/show?id=ac8de440615' target=_blank style='color:#2F92EE;'>#神经痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74406, encryptionId=ac8de440615, topicName=神经痛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d8213287489, createdName=贵阳, createdTime=Thu Sep 16 01:55:59 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580470, encodeId=3f9c15804e0db, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Thu Sep 16 01:55:59 CST 2021, time=2021-09-16, status=1, ipAttribution=)]

相关资讯

Gastroenterology:警惕JAK抑制剂治疗导致患者带状疱疹风险增加

接受JAK抑制剂治疗的免疫相关疾病患者带状疱疹风险显著增加

GSK携手北京协和医学院群医学及公共卫生学院:以带状疱疹疾病医防协同为试点,,关注中老年人疫苗可预防疾病

11月6日,葛兰素史克 (GSK) 与中国医学科学院北京协和医学院群医学及公共卫生学院于第三届进博会上签订了公益项目合作备忘录,北京协和医学院群公学院教授、执行院长杨维中,GSK副总裁、中国处方药和疫

双侧双重带状疱疹

患者女,64 岁。 因左侧头面及右侧腰腹部出现簇 集水疱伴疼痛 7 d 至我院就诊。患者 7 d 前无明显诱因 左侧头皮、额面部疼痛不适,呈间歇性刺痛,不久左侧 头皮、额部开始出现片状红斑,其上见散在

BMJ:幼儿期接受暴露于水痘后对成人期带状疱疹发病率的影响

婴幼儿时期暴露于水痘危险中对其成人后带状疱疹的发病率究竟是怎样的呢?

BMJ:家庭中水痘患儿可降低成年人带状疱疹风险

研究发现,家庭中存在儿童水痘患儿可降低成人的带状疱疹风险,这一风险降低效果适中且可以长期保持

疱疹消失了为何还疼得睡不着觉?医生:应该这样治疗和预防

时值春季,万物复苏,病毒、细菌也蠢蠢欲动,是各种传染性疾病的高发季节。带状疱疹爱在春秋找人麻烦,需小心防范。

Baidu
map
Baidu
map
Baidu
map